ARNA

Arena Pharmaceuticals, Inc. [ARNA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ARNA Stock Summary

In the News

11:04 29 Mar 2024 ARNA

Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals

Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year.

06:24 29 Mar 2024 ARNA

7 Biotech Stocks With Key Catalysts in March

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.

03:05 29 Mar 2024 ARNA

11 Marijuana Stocks on Fire to Close February

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

07:15 29 Mar 2024 ARNA

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

07:30 29 Mar 2024 ARNA

Top 3 weed stocks to put on your watch list this year

The marijuana industry has seen sharp growth year on year.

04:33 29 Mar 2024 ARNA

Pharma Giants Go After $10 Billion Market With RSV Drugs

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.

12:01 29 Mar 2024 ARNA

Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment

Pfizer Inc.'s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis.

11:28 29 Mar 2024 ARNA

Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

10:13 29 Mar 2024 ARNA

Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022

Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning.

10:44 29 Mar 2024 ARNA

Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

ARNA Financial details

Company Rating
Neutral
Market Cap
0
Income
-617.44M
Revenue
54K
Book val./share
10.97
Cash/share
8.97
Dividend
-
Dividend %
-
Employees
448
Optionable
Yes
Shortable
Yes
Earnings
04 May 2022
P/E
-8.82
Forward P/E
-
PEG
-2.37
P/S
-
P/B
8.13
P/C
11.15
P/FCF
-
Quick Ratio
8.3
Current Ratio
8.59
Debt / Equity
0.06
LT Debt / Equity
0.05
-
-
EPS (TTM)
-10.14
EPS next Y
-
EPS next Q
-
EPS this Y
53.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
32.54%
Revenue last 5Y
-69.76%
Revenue Q/Q
-
EPS Q/Q
-20.56%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
1%
ROA
-79%
ROE
-71%
ROC
-0.85%
Gross Margin
100%
Oper. Margin
-1133841%
Profit Margin
-1149244%
Payout
-
Shs Outstand
61.66M
Shs Float
61.52M
-
-
-
-
Target Price
94
52W Range
99.97-100
52W High
-0.01%
52W Low
+1%
RSI
-
Rel Volume
-
Avg Volume
1.47M
Volume
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.54872
-
-
Volatility
0%, 0%
Prev Close
0%
Price
99.99
Change
0.02%

ARNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.650.3815.60.010
Net income per share
-2.77-0.627.69-7.39-11.33
Operating cash flow per share
-2.02-2.8111-6.45-8.25
Free cash flow per share
-2.02-2.8310.91-6.46-9.55
Cash per share
7.499.4714.3120.1610.05
Book value per share
6.2812.8920.7319.7312.29
Tangible book value per share
6.2812.8920.7319.7312.29
Share holders equity per share
6.2812.8920.7319.7312.29
Interest debt per share
0.310.190.170.160.83
Market cap
1.12B1.83B2.35B4.21B5.09B
Enterprise value
1.02B1.72B2.15B4.03B4.91B
P/E ratio
-12.26-62.325.91-10.4-8.2
Price to sales ratio
52.52101.962.9113.19K94.26K
POCF ratio
-16.82-13.864.13-11.92-11.26
PFCF ratio
-16.79-13.794.16-11.89-9.73
P/B Ratio
5.413.022.193.897.56
PTB ratio
5.413.022.193.897.56
EV to sales
47.9795.932.6712.65K90.86K
Enterprise value over EBITDA
-12.64-13.244.18-10.18-8.06
EV to operating cash flow
-15.36-13.043.79-11.42-10.86
EV to free cash flow
-15.33-12.973.82-11.4-9.38
Earnings yield
-0.08-0.020.17-0.1-0.12
Free cash flow yield
-0.06-0.070.24-0.08-0.1
Debt to equity
0.020.01000.06
Debt to assets
0.010000.05
Net debt to EBITDA
1.20.83-0.380.440.3
Current ratio
3.8915.416.919.628.59
Interest coverage
-15.03-25.42100.76-94.33-147.22
Income quality
0.734.51.430.870.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.422.650.1323.512.34K
Research and developement to revenue
3.336.40.291.01K7.77K
Intangibles to total assets
00000
Capex to operating cash flow
00.01-0.0100.16
Capex to revenue
-0.01-0.04-0.01-2.57-1.31K
Capex to depreciation
-0.03-0.18-1.49-0.21-18.33
Stock based compensation to revenue
0.371.090.07187.841.3K
Graham number
19.7813.4659.8857.2755.98
ROIC
-0.35-0.040.34-0.4-0.82
Return on tangible assets
-0.27-0.040.34-0.34-0.79
Graham Net
3.817.8412.3418.158.02
Working capital
208.95M430.81M714.97M1.08B503.15M
Tangible asset value
207.14M606.26M1.07B1.08B673.24M
Net current asset value
149.15M380.08M657.28M1.03B458M
Invested capital
0.020.01000.06
Average receivables
17.27M9.73M3.37M827K0
Average payables
3.79M3.9M6.12M9.02M12.65M
Average inventory
3.35M0000
Days sales outstanding
246.02103.30.7500
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.483.53487.5600
Payables turnover
00000
Inventory turnover
00000
ROE
-0.44-0.050.37-0.37-0.92
Capex per share
0-0.01-0.09-0.01-1.3

Quarterly Fundamentals Overview

Last date of statement is 2021-12-31 for Q4

Metric History 2020-12-312021-03-312021-06-302021-09-30 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.1-1.98-2.4-3.21-2.55
Operating cash flow per share
-1.83-2.01-1.54-1.92-1.96
Free cash flow per share
-1.83-2.01-1.55-3.07-1.97
Cash per share
18.9418.2115.9812.628.97
Book value per share
18.5418.1715.9813.110.97
Tangible book value per share
18.5418.1715.9813.110.97
Share holders equity per share
18.5418.1715.9813.110.97
Interest debt per share
0.090.750.730.710.69
Market cap
4.48B4.15B4.15B3.64B5.7B
Enterprise value
4.3B3.76B3.67B3.3B5.52B
P/E ratio
-9.16-8.76-7.09-4.64-9.11
Price to sales ratio
121.03K000105.64K
POCF ratio
-42.1-34.57-44.18-30.94-47.34
PFCF ratio
-42.04-34.54-44.08-19.38-47.13
P/B Ratio
4.143.824.274.558.47
PTB ratio
4.143.824.274.558.47
EV to sales
116.33K000102.24K
Enterprise value over EBITDA
-35.84-32.01-25.51-16.97-35.93
EV to operating cash flow
-40.46-31.33-39.16-28.01-45.82
EV to free cash flow
-40.41-31.31-39.08-17.55-45.62
Earnings yield
-0.03-0.03-0.04-0.05-0.03
Free cash flow yield
-0.02-0.03-0.02-0.05-0.02
Debt to equity
00.040.040.050.06
Debt to assets
00.040.040.050.05
Net debt to EBITDA
1.453.313.271.771.19
Current ratio
19.6223.6115.2814.828.59
Interest coverage
-123.450-137.38-188.64-153.99
Income quality
0.871.010.640.60.77
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
943.24000638.89
Research and developement to revenue
2.71K0002.04K
Intangibles to total assets
00000
Capex to operating cash flow
0000.60
Capex to revenue
-3.68000-9.87
Capex to depreciation
-0.14-0.1-0.21-72.25-0.56
Stock based compensation to revenue
544.68000338.26
Graham number
29.5728.4529.3930.7625.09
ROIC
-0.13-0.13-0.14-0.22-0.21
Return on tangible assets
-0.1-0.1-0.13-0.22-0.2
Graham Net
17.0516.5814.1110.987.15
Working capital
1.08B1.07B925.6M737.57M503.15M
Tangible asset value
1.08B1.09B971.08M800.72M673.24M
Net current asset value
1.03B1.02B876.86M690.61M458M
Invested capital
00.040.040.050.06
Average receivables
00000
Average payables
9.84M10.78M6.67M5.36M10.12M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.11-0.15-0.25-0.23
Capex per share
000-1.15-0.01

ARNA Frequently Asked Questions

What is Arena Pharmaceuticals, Inc. stock symbol ?

Arena Pharmaceuticals, Inc. is a US stock , located in San diego of California and trading under the symbol ARNA

Is Arena Pharmaceuticals, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $94. The lowest prediction is $90 and the highest is $100

What is ARNA stock prediction ?

What is Arena Pharmaceuticals, Inc. stock quote today ?

Arena Pharmaceuticals, Inc. stock price is $99.99 today.

Is Arena Pharmaceuticals, Inc. stock public?

Yes, Arena Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap